Eventide Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Eventide Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-128,240	Closed	-$8.57M	–	133
2016 Q1	$8.57M	Hold	128,240	–	–	0.48%	58
2015 Q4	$8.67M	Sell	128,240 -53,701	-30%	-$3.32M	0.43%	62
2015 Q3	$9.72M	Hold	181,941	–	–	0.56%	55
2015 Q2	$11.5M	Hold	181,941	–	–	0.62%	53
2015 Q1	$8.75M	Sell	181,941 -58,028	-24%	-$2.22M	0.66%	58
2014 Q4	$7.97M	Hold	239,969	–	–	0.87%	52
2014 Q3	$7.03M	Hold	239,969	–	–	0.98%	43
2014 Q2	$9.32M	Buy	239,969 +2,885	+1%	+$117K	1.27%	36
2014 Q1	$9.95M	Buy	237,084 +21,641	+10%	+$902K	1.54%	26
2013 Q4	$7.07M	Buy	+215,443	New	+$7.02M	2.18%	11

Other funds holding LGND

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Eventide Asset Management's LGND Position: Q2 2016 in Review

Eventide Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2016, closing a stake of 128,240 shares — an estimated $8.57M sold.

Eventide Asset Management first reported a position in LGND in Q4 2013 and held it in 10 quarters. The position peaked at $11.5M in Q2 2015. 265 funds tracked by Wall St. Rank hold LGND as of Q2 2016.

Eventide Asset Management reported no remaining Ligand Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Eventide Asset Management sold 128,240 Ligand Pharmaceuticals shares in Q2 2016, an estimated $8.57M.
Eventide Asset Management first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Eventide Asset Management's Ligand Pharmaceuticals position peaked at $11.5M in Q2 2015.
265 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2016.

Based on Eventide Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.